PMID- 34349832
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210806
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - A Network Pharmacology Approach to Investigate the Mechanism of Erjing 
      Prescription in Type 2 Diabetes.
PG  - 9933236
LID - 10.1155/2021/9933236 [doi]
LID - 9933236
AB  - Erjing prescription (EJP) was an ancient formula that was recorded in the General 
      Medical Collection of Royal Benevolence of the Song Dynasty. It has been 
      frequently used to treat type 2 diabetes mellitus (T2DM) in the long history of 
      China. The formula consists of Lycium barbarum L. and Polygonatum sibiricum F. 
      Delaroche with a ratio of 1 : 1. This study aimed to identify the potential 
      effects and mechanisms of EJP treatment T2DM. The target proteins and possible 
      pathways of EJP in T2DM treatment were investigated by the approach of network 
      pharmacology and real-time PCR (RT-PCR). 99 diabetes-related proteins were 
      regulated by 56 bioactive constituents in EJP in 26 signal pathways by Cytoscape 
      determination. According to GO analysis, 606 genes entries have been enriched. 
      The PPI network suggested that AKT1, EGF, EGFR, MAPK1, and GSK3beta proteins were 
      core genes. Among the 26 signal pathways, the PI3K-AKT signal pathway was tested 
      by the RT-PCR. The expression level of PI3K p85, AKT1, GSK3beta, and Myc mRNA of 
      this pathway was regulated by EJP. The study based on network pharmacology and 
      RT-PCR analysis revealed that the blood sugar level was regulated by EJP via 
      regulating the PI3K-AKT signal pathway. Plenty of new treatment methods for T2DM 
      using EJP were provided by network pharmacology analysis.
CI  - Copyright (c) 2021 Jiexin Wang et al.
FAU - Wang, Jiexin
AU  - Wang J
AD  - College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
FAU - Chu, Haiqing
AU  - Chu H
AD  - College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
FAU - Li, Hangying
AU  - Li H
AD  - College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
AD  - Ningxia Engineering and Technology Research Center for Modernization of Chinese 
      Medicine, Yinchuan 750004, China.
FAU - Yang, Wenqian
AU  - Yang W
AD  - College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
FAU - Zhao, Yu
AU  - Zhao Y
AD  - College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
FAU - Shen, Tong
AU  - Shen T
AD  - College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
FAU - Cary, John
AU  - Cary J
AD  - Ningxia Medical University, Yinchuan 750004, China.
FAU - Zhang, Liming
AU  - Zhang L
AUID- ORCID: 0000-0003-0575-2781
AD  - College of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
AD  - Ningxia Engineering and Technology Research Center for Modernization of Chinese 
      Medicine, Yinchuan 750004, China.
AD  - Key Laboratory of Ningxia Ethnomedicine Modernization, Ministry of Education, 
      Ningxia Medical University, Yinchuan 750004, China.
LA  - eng
PT  - Journal Article
DEP - 20210724
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8328705
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
PMCR- 2021/07/24
CRDT- 2021/08/05 06:25
PHST- 2021/03/04 00:00 [received]
PHST- 2021/07/11 00:00 [revised]
PHST- 2021/07/17 00:00 [accepted]
PHST- 2021/08/05 06:25 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
PHST- 2021/07/24 00:00 [pmc-release]
AID - 10.1155/2021/9933236 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Jul 24;2021:9933236. doi: 
      10.1155/2021/9933236. eCollection 2021.